البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
ESCITALOPRAM (ESCITALOPRAM OXALATE)
RANBAXY PHARMACEUTICALS CANADA INC.
N06AB10
ESCITALOPRAM
10MG
TABLET
ESCITALOPRAM (ESCITALOPRAM OXALATE) 10MG
ORAL
100/500
Prescription
SELECTIVE-SEROTONIN REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0150435002; AHFS:
APPROVED
2015-05-05
_ _ _Pr_ _ESCITALOPRAM (Escitalopram Tablets, Mfr. Std.) Product Monograph _ _Page 1 of 59_ PRODUCT MONOGRAPH PR ESCITALOPRAM Escitalopram Tablets, Mfr. Std. 10 mg and 20 mg escitalopram (as escitalopram oxalate) ANTIDEPRESSANT / ANTIOBSESSIONAL Ranbaxy Pharmaceuticals Canada Inc. DATE OF PREPARATION: 2680 Matheson Blvd. E., Suite 200 March 24, 2015 Mississauga, Ontario L4W 0A5 SUBMISSION CONTROL NO: 181798 Trademark owned by Ranbaxy Laboratories Limited _ _ _Pr_ _ESCITALOPRAM (Escitalopram Tablets, Mfr. Std.) Product Monograph _ _Page 2 of 59_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................12 DRUG INTERACTIONS ..................................................................................................26 DOSAGE AND ADMINISTRATION ..............................................................................32 OVERDOSAGE ................................................................................................................35 ACTION AND CLINICAL PHARMACOLOGY ............................................................36 STORAGE AND STABILITY ..........................................................................................38 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................38 PART II: SCIENTIFIC INFORMATION ...............................................................................39 PHARMACEUTICAL INFORMATION .............................. اقرأ الوثيقة كاملة